gsk 257049
Vaccineexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
11
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2005 (NCT00323622)
Timeline
Indications
Studied for
Mechanism of action
- Plasmodium vivaxImmunity, active
Plasmodium vivax immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk257049
- gsk 257049
- malaria vaccine 257049
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01857869 | Phase 2 | May 1, 2013 | GlaxoSmithKline, PATH, United States Army |
| NCT01345240 | Phase 3 | Nov 1, 2011 | GlaxoSmithKline |
| NCT01366534 | Phase 2 | Aug 10, 2011 | Crucell, GlaxoSmithKline, PATH |
| NCT01323972 | Phase 3 | May 16, 2011 | GlaxoSmithKline, PATH |
| NCT01231503 | Phase 2 | Jan 1, 2011 | GlaxoSmithKline, PATH |
| NCT00866619 | Phase 3 | Mar 27, 2009 | GlaxoSmithKline, PATH |
| NCT00436007 | Phase 2 | Apr 30, 2007 | GlaxoSmithKline |
| NCT00443131 | Phase 2 | Mar 26, 2007 | GlaxoSmithKline |
| NCT00380393 | Phase 2 | Jan 3, 2007 | GlaxoSmithKline |
| NCT00307021 | Phase 2 | Apr 7, 2006 | GlaxoSmithKline |
| NCT00323622 | Phase 2 | Apr 1, 2005 | GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 11 | 2 | 2005 |
| PATH | Academic/Hospital | 5 | 0 | 2 | 2009 |
| Crucell | For profit | 1 | 0 | 1 | 2011 |
| United States Army | Government | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1